Overview

A Clinical Study to Assess the Safety of PEG-Hirudin (SPP200) Compared to Heparin in Patients Who Are on Haemodialysis

Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
The study will look at the safety profile (unwanted effects) of the long-lasting anticoagulant PEG-hirudin (SPP200) and compare these unwanted effects to those of unfractionated heparin, commonly used in haemodialysis to avoid clotting of the graft and of the haemodialysis machine.
Phase:
Phase 2
Details
Lead Sponsor:
Speedel Pharma Ltd.
Collaborator:
Quintiles, Inc.
Treatments:
Heparin
Hirudins